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Normal pregnancy in a patient with b-thalassaemia major
receiving iron chelation therapy with deferasirox (Exjade
 )
To the Editor:
Improvements in managing b-thalassaemia major have
allowed many patients to survive beyond puberty. Fertil-
ity can, however, be impaired as a result of iron over-
load-related hypogonadism (1), although assisted
reproductive techniques and advances in treating iron
overload have increased the number of successful preg-
nancies in such patients (2–9). During pregnancy,
patients may require additional blood transfusions to
treat complications such as pre-eclampsia or severe anae-
mia, increasing the need for effective iron chelation ther-
apy. Clinical data are limited regarding the use of
chelation therapy during pregnancy, and it is unclear
whether these agents pose any risk to the developing foe-
tus. However, there are case reports of successful preg-
nancies following treatment with deferoxamine
(Desferal
 ; Novartis Pharmaceuticals Corp, East Hano-
ver, NJ, USA) (10, 11). This case study discusses a
patient who became pregnant while receiving deferasirox
(Exjade
 ; Novartis Pharmaceuticals Corp), the once-
daily, oral iron chelator. As deferasirox use is contraindi-
cated during pregnancy, no recommendation can be
made on the safety of iron chelation in pregnancy.
The 35-yr-old female patient (born June 1972) was
diagnosed with b-thalassaemia major at 8 months of age.
She has received red blood cell (RBC) transfusions since
diagnosis and was treated with continuous deferoxamine
from the age of 6 yr. Due to poor compliance and subse-
quent lack of efﬁcacy, she was switched to deferiprone
monotherapy (Ferriprox
 ; Apotex Inc., Toronto, ON,
Canada) aged 29 yr. She received deferiprone for 2 yr,
before switching to deferoxamine and⁄or deferiprone
because of a lack of efﬁcacy; she remained on this regi-
men until August 2006. The patient had her ﬁrst menstru-
ation at the age of 12 and had regular menstrual cycles
until she was 30 yr old, when hormonal replacement ther-
apy was required. She was splenectomised aged 27 yr.
Obstetric history included two planned abortions and one
successful pregnancy by in vitro fertilisation. She did not
receive any chelation therapy during this pregnancy.
The patient was switched to deferasirox in August
2006 following enrolment into a clinical trial; at this
point, she was receiving two RBC units every 20 d. Prior
to enrolment, her compliance with deferoxamine had
been poor, which led to substantially elevated body iron
levels; the patient’s clinical characteristics at this time are
shown in Table 1. Deferasirox treatment was initiated at
a dose of 18.9 mg⁄kg⁄d. Before starting deferasirox, a
serum b-hCG pregnancy test was performed and proved
negative. The dose was increased to 23.6 mg⁄kg⁄d after
3 months (November 2006) because of slow decrease in
serum ferritin and increased weight. A mild skin rash
was initially observed, although this resolved spontane-
ously without discontinuing deferasirox treatment. The
patient also experienced persistent constipation for which
she received lactulose (Duphalac
 ; Solvay S.A., Brussels,
Belgium).
During a random examination by her gynaecologist on
24 December 2006, the patient was conﬁrmed to be
22 wk pregnant; her last menstruation occurred 4 August
2006. During this period, the patient was receiving hor-
mone replacement therapy. This second pregnancy was
spontaneous. Deferasirox treatment was stopped immedi-
ately, at which point serum ferritin levels had decreased
by >1000 ng⁄mL (Table 1). From the 17th week until
the conﬁrmation of pregnancy, the patient’s haemoglobin
level decreased (average 7.5–8.0 g⁄dL). Once deferasirox
was withdrawn, the patient’s constipation resolved com-
pletely, suggesting it may have been treatment related.
Cardiac function, as assessed by Triplex and Doppler
(General Electric Logiq), was normal during follow-up.
Table 1 Patient’s clinical characteristics when switching to and stop-
ping deferasirox treatment
Characteristic
Baseline values
when switching
to deferasirox
Values when deferasirox
stopped (conﬁrmation of
pregnancy)
Haemoglobin (g⁄dL) 9.8 10.1
Haematocrit (%) 29.5 30.7
Serum ferritin (ng⁄mL) 3681 2431
Weight (kg) 53 55
AST (U⁄L) 19 18
ALT (U⁄L) 38 33
Serum creatinine (mg⁄dL) 0.7 0.4
AST, aspartate aminotransferase; ALT, alanine aminotransferase.
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output were normal. Close monitoring of development
via ultrasound was performed monthly throughout the
pregnancy.
During pregnancy, the patient received an average of
5 RBC units⁄month until the end of April 2007. Serum
ferritin levels after stopping chelation (during 2007) were
as follows: January, 2721; February, 2431; March, 2357;
April, 2311; May, 2743 and June, 2264 ng⁄mL. Since
serum ferritin levels did not increase, the foetus may
have acted as a natural chelator. Diabetes of gestation,
which was also noted during her ﬁrst pregnancy, was
observed at 31 wk and required insulin treatment; the
investigator considered this to be serious but not related
to deferasirox treatment. A caesarean section was per-
formed in May 2007 at 37 wk gestation. The baby was a
normal female: weight 2.59 kg (5.7 lbs), height 47.3 cm,
head circumference 33 cm and Apgar score normal
(8 after 1 min). Birthweight, height and Apgar score were
comparable to that of the child’s older sibling, who is
also female: birthweight 2.40 kg (5.3 lbs), height 51 cm,
head circumference 32 cm and Apgar score normal.
In conclusion, this is the ﬁrst report describing the use
of deferasirox during pregnancy. In this case, treatment
up to 22 wk gestation was well tolerated and did not pre-
vent delivery of a healthy baby. The child is now 4 yr
old and is developing normally. It should be noted that
the use of deferasirox is contraindicated in pregnant
women based on the approved product label.
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